⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KZIA News
Kazia Therapeutics Limited American Depositary Shares
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
prnewswire.com
KZIA
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
prnewswire.com
KZIA
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
prnewswire.com
KZIA
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
prnewswire.com
ONCY
BCTX
GLSI
CTOR
KZIA
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
prnewswire.com
KZIA
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
prnewswire.com
KZIA
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
prnewswire.com
KZIA
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
prnewswire.com
KZIA
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
prnewswire.com
KZIA
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
prnewswire.com
KZIA
KZIA